Sands BE, Taub PR, Armuzzi A, et al. - Data from 1,157 individuals who took part in three 8-week induction studies, a 52-week phase-3 maintenance study of responders, and an ongoing long-term extension study of individuals who did and did not react to initiation or maintenance therapy was included to investigate inflammation, lipid concentrations, and incidence rates of major adverse cardiovascular (CV) events (MACEs) in patients who received tofacitinib in global studies for ulcerative colitis (UC). Reversible elevations in lipids with treatment and inverse associations with decreased levels of high-sensitivity C-reactive protein were discovered in this analysis of data from trials of individuals with UC who received tofacitinib. Moreover, clinically significant variations in lipid ratios or Reynolds risk score was not seen. Also, MACEs were occasional and were not associated with the dose of the tofacitinib.